FindTrial
Sign In

The safety and scientific validity of low-dose whole brain radiotherapy on brain amyloidosis during the treatment of mild or moderate Alzheimer’s disease.

The safety and scientific validity of low-dose whole brain radiotherapy on brain amyloidosis during the treatment of mild or moderate Alzheimer’s disease.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0003582
Enrollment
10
Registered
2019-03-05
Start date
2019-03-25
Completion date
Unknown
Last updated
2019-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Kyung Hee University Hosipital at Gangdong
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Clinical diagnosis of mild or moderate Alzheimer's disease. 2. Amyloid PET(positron emission tomography scan) positivity. 3. Korean Mini-Mental State Examination score =10 and =24. 4. Clinical dementia rating scale 0.5, 1 or 2. 5. Male and female subjects aged 50 to 85 years. 6. Able to complete neurocognitive function assessments, psychological function assessments, and QOL(Quality of Life) assessments administered at the screening visit. 7. Subjects with a caregiver who provided information about the overall status of the subject and the changes in cognitive function and function. 8. Signed by research subject or guardian who understands the qualifications for the study and signs the consent form.

Exclusion criteria

Exclusion criteria: 1. Current or past history of whole brain radiotherapy 2. Evidence of seizure activity 3. Evidence of active dermatological skin disease of the scalp. 4. History of malignant tumors. 5. Pregnant or breastfeeding. 6. If the researcher determines that participation in this study is inadequate because of other findings that are considered clinically important.

Design outcomes

Primary

MeasureTime frame
After first visitng 6months , evaluate for scoring change compared with baseline study using neurocognitive testing methods (K-MMSE(Korean Mini Mental State Examination), verbal memory, visual memory, Korean version-Boston Naming Test, Clock Drawing Test, Controlled Oral Word Association Test, Stroop Test).;The change in SUV of flutametamol (18F) amyloid PET on the Frontal, Posterior cingulate and Precuneous, Lateral Temporal region, Parietal lobe, Striatum.—

Secondary

MeasureTime frame
For verifying of adverse effect about headache, nausea, vomiting,anorexia,general fatigue, redness and itching of scalp,alopecia—

Countries

Korea, Republic of

Contacts

Public ContactWeonkuu Chung

Kyung Hee University Hosipital at Gangdong

wkchung16@gmail.com+82-2-440-6071

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026